Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by AbbVie
Information provided by (Responsible Party):
AbbVie Identifier:
First received: May 3, 2013
Last updated: January 13, 2017
Last verified: January 2017
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Ulcerative Colitis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC [ Time Frame: 10 years observational period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy [ Time Frame: 10 years observational period ] [ Designated as safety issue: No ]

Estimated Enrollment: 8250
Study Start Date: April 2013
Estimated Study Completion Date: April 2027
Estimated Primary Completion Date: April 2027 (Final data collection date for primary outcome measure)
Adalimumab (Humira) Treatment
Patients who are prescribed and treated with Adalimumab
Immunomodulatory Therapy
Patients who are being prescribed and treated with Immunomodulatory Therapy


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients with moderately to severely active Ulcerative Colitis (UC) who have been prescribed HUMIRA according to the local label and adult patients being prescribed and treated with IMM (6-mercaptopurine or azathioprine) with no concurrent biologic use.

Inclusion Criteria:

  • For enrollment into the HUMIRA treatment group; adult patients with moderately to severely active UC who has been prescribed HUMIRA therapy according to routine clinical practice and meets one of the following:

    1. Is currently taking HUMIRA therapy and has received at least 8 weeks of therapy; OR
    2. Is entering after participation in an Abbott or AbbVie sponsored UC study and; has received continuous HUMIRA therapy since initiation of therapy
  • For enrollment into the IMM treatment group; adult patients with moderately to severely active UC who has been prescribed IMM therapy, is currently taking IMM therapy, and has received at least 12 consecutive weeks of IMM therapy
  • Patients capable of and willing to grant authorization for use/disclosure of data being collected and provided to AbbVie prior to any registry-related data being collected, and to comply with the requirements of the Registry protocol

Exclusion Criteria:

  • Patients on IMM therapy without a concurrent biologic if they cannot continue to be treated with IMM therapy or
  • Patients who are being treated with any investigational agents and/or approved biologics other than Humira.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01848561

Contact: Marilyn Wanca, BS 847-937-2375
Contact: Eva Perotti, BS 847-938-9243

  Show 585 Study Locations
Sponsors and Collaborators
Study Director: Alexandra Song, MD AbbVie
  More Information

Additional Information:
Responsible Party: AbbVie Identifier: NCT01848561     History of Changes
Other Study ID Numbers: P11-282 
Study First Received: May 3, 2013
Last Updated: January 13, 2017
Health Authority: Ireland: Research Ethics Committee
Austria: Federal Office for Safety in Health Care
France: Conseil National de l'Ordre des Médecins
Italy: The Italian Medicines Agency
Denmark: Danish Dataprotection Agency
France: French Data Protection Authority
Norway: Regional Ethics Commitee
Sweden: Regional Ethical Review Board
Germany: Paul-Ehrlich-Institut
Denmark: Danish Health and Medicines Authority
Belgium: Ethics Committee
Spain: Agencia Española de Medicamentos y Productos Sanitarios
New Zealand: Medsafe
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Australia: Human Research Ethics Committee
Israel: Ethics Commission
Greece: Ethics Committee
Norway: Norwegian Medicines Agency
Canada: Health Canada
Croatia: Agency for Medicinal Product and Medical Devices
Greece: National Organization of Medicines
Mexico: Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AbbVie:
Inflammatory Bowel Diseases
Ulcerative Colitis
Gastrointestinal Diseases

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on January 17, 2017